Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Cell cycle (Georgetown, Tex.) - 1 Feb 2009

Krymskaya Vera P, Goncharova Elena A

Abstract excerpt

Dysregulated activity of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin complex 1 (mTORC1) is characteristic feature of hamartoma syndromes. Hamartoma syndromes, dominantly inherited cancer predisposition disorders, affect multiple organs and are manifested by benign tumors consisting of various cell types native to the tissues in which they arise. In the past few years, three inherited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Enzyme Inhibitors
Share to Hamartoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Multiprotein Complexes

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 19177005
DOI: 10.4161/cc.8.3.7555
PMCID: PMC3718392

Genes

PTEN
TSC1
TSC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.PMID 19177005Read ↗

PTEN hamartoma tumor syndromes.Semantic proximity Read ↗

PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic DiseasesSemantic proximity Read ↗

PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney CystsSemantic proximity Read ↗

Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatmentSemantic proximity Read ↗

The PTEN–PI3K Axis in CancerSemantic proximity Read ↗

PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.Semantic proximity Read ↗

Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.Semantic proximity Read ↗

The tuberous sclerosis complex genes in tumor development.Semantic proximity Read ↗

Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.Semantic proximity Read ↗

The PTEN-PI3K Axis in CancerSemantic proximity Read ↗

mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex ModelSemantic proximity Read ↗

Dysregulation of the TSC-mTOR pathway in human diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.